| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $217.6M | -19.1% |
| SG&A Expense | $64.0M | -12.6% |
| Operating Income | -$272.7M | +7.0% |
| Net Income | -$266.8M | +5.8% |
| EPS (Basic) | -$1.16 | +20.5% |
| EPS (Diluted) | -$1.16 | +20.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $127.6M | -4.5% |
| Short-term Investments | $24.9M | -65.2% |
| Current Assets | $160.8M | -24.7% |
| Total Assets | $501.0M | -11.4% |
| Current Liabilities | $45.4M | -29.5% |
| Total Liabilities | $250.5M | -9.8% |
| Stockholders' Equity | $250.5M | -12.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$223.2M | +12.0% |
| Capital Expenditures | $33.4M | +66.9% |
| Investing Cash Flow | $17.5M | -89.9% |
| Financing Cash Flow | $199.7M | +531.2% |
| Free Cash Flow | -$256.6M | +6.2% |